Perigon Wealth Management LLC Has $828,000 Stake in TransMedics Group, Inc. (NASDAQ:TMDX)

Perigon Wealth Management LLC increased its holdings in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 212.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 14,277 shares of the company’s stock after acquiring an additional 9,707 shares during the period. Perigon Wealth Management LLC’s holdings in TransMedics Group were worth $828,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Principal Financial Group Inc. raised its stake in shares of TransMedics Group by 260.1% in the third quarter. Principal Financial Group Inc. now owns 202,287 shares of the company’s stock worth $31,759,000 after acquiring an additional 146,115 shares during the last quarter. Public Sector Pension Investment Board acquired a new stake in shares of TransMedics Group in the third quarter valued at approximately $11,079,000. Connor Clark & Lunn Investment Management Ltd. raised its position in TransMedics Group by 665.1% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 74,625 shares of the company’s stock worth $11,716,000 after purchasing an additional 64,872 shares during the last quarter. Vaughan Nelson Investment Management L.P. raised its position in TransMedics Group by 24.3% in the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 329,010 shares of the company’s stock worth $51,654,000 after purchasing an additional 64,360 shares during the last quarter. Finally, Handelsbanken Fonder AB lifted its holdings in TransMedics Group by 657.6% during the 3rd quarter. Handelsbanken Fonder AB now owns 64,400 shares of the company’s stock worth $10,111,000 after buying an additional 55,900 shares in the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

TransMedics Group Price Performance

Shares of TMDX stock opened at $66.95 on Friday. The firm has a market capitalization of $2.25 billion, a price-to-earnings ratio of 71.22 and a beta of 2.12. TransMedics Group, Inc. has a 12-month low of $55.00 and a 12-month high of $177.37. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. The firm has a fifty day moving average of $67.70 and a 200-day moving average of $113.12.

TransMedics Group (NASDAQ:TMDX) last announced its quarterly earnings results on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.17). TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The business had revenue of $108.76 million during the quarter, compared to the consensus estimate of $115.00 million. During the same quarter last year, the company earned ($0.12) earnings per share. The firm’s revenue was up 63.7% compared to the same quarter last year. On average, equities research analysts forecast that TransMedics Group, Inc. will post 1 earnings per share for the current year.

Insider Activity at TransMedics Group

In other TransMedics Group news, Director Edward M. Basile sold 6,750 shares of TransMedics Group stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $83.55, for a total value of $563,962.50. Following the sale, the director now owns 732 shares of the company’s stock, valued at $61,158.60. This trade represents a 90.22 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Tamer I. Khayal sold 1,084 shares of the business’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $86.40, for a total value of $93,657.60. Following the completion of the sale, the insider now owns 20,843 shares in the company, valued at approximately $1,800,835.20. This trade represents a 4.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.00% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on TMDX shares. TD Cowen dropped their target price on TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a research report on Monday, November 18th. Robert W. Baird dropped their price objective on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a report on Wednesday, December 11th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $75.00 target price (down previously from $116.00) on shares of TransMedics Group in a research note on Tuesday, December 17th. Needham & Company LLC reissued a “hold” rating on shares of TransMedics Group in a research note on Wednesday, December 11th. Finally, Canaccord Genuity Group reduced their price objective on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating on the stock in a research note on Wednesday, November 20th. Three analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $122.70.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.